Kurt Kamrud

Director Genomic Platforms @CEVA SALUD ANIMAL

Lenexa, KS, US

Dr. Kurt Kamrud is the Director of the Genomic Platforms Group within Science and Innovation Direction at Ceva Animal Health in Lenexa, KS. He has over 25 years of experience in molecular virology. Before joining Ceva Animal Health, Dr. Kamrud was Director of the Discovery Group at AlphaVax Inc. in the Research Triangle Park, Durham, NC. AlphaVax was focused on development of an alphavirus replicon-particle platform for human vaccine development. Dr. Kamrud lead a team that developed the alphavirus replicon vaccine technology, pushed vaccine targets through pre-clinical testing and transferred these targets to the manufacturing group to support cGMP vaccine production. The AlphaVax replicon-particle technology was advanced through Phase 2 human clinical trials. After 10 years at AlphaVax, Dr. Kamrud became Vice President of Research and Chief Scientific Officer at Harrisvaccines in Ames, IA. Harrisvaccines is a veterinary vaccine company focused on alphavirus replicon particle-based vaccines. While at Harrisvaccines, Dr. Kamrud successfully lead the effort to fully license alphavirus replicon particle-based vaccines for veterinary use with the USDA. Harrisvaccines was acquired by Merck Animal Health in 2016. Most recently, Dr Kamrud was Vice President of the RNA Medicines group at Synthetic Genomics, Inc.(SGI) in La Jolla, CA where he lead a self-amplifying RNA replicon platform development program focused on vaccine and therapeutic applications for more than 5 years.Dr. Kamrud received his Ph.D. in Microbiology (molecular virology) from Colorado State University, Fort Collins, CO. Prior to earning his Ph.D. he earned a M.S. in Microbiology from Hood College, Frederick, MD and a B.A. in Computer Science and Biology from Concordia College, Moorhead, MN.

Colorado State University

Ph.D., Microbiology, Virology